Notably, compound #2 preferentially inhibited rSmTAChE (IC50 = 0.74 μM) over human AChE (IC50 = 151 μM), thus providing a foundation for developing parasite-specific therapies targeting SmTAChE and potentially leading to new treatments for schistosomiasis. This evidence concerns the gene ACHE and schistosomiasis.